Jansen J W
Arzneimittelforschung. 1987 May;37(5A):626-8.
The non-steroidal antiinflammatory drug benzydamine (Tantum) was studied for antithrombotic properties. In vitro, rat platelet aggregation induced by adenosine diphosphate (ADP) and collagen was inhibited (IC50 about 10(-4) mol/l) and malondialdehyde formation induced by arachidonic acid in dog platelets was not influenced. The classical non-steroidal antiinflammatory drugs as indomethacin showed opposite effects. In vivo benzydamine hardly inhibited pulmonary thromboembolism induced by arachidonic acid in mice, which indicates again that the cyclooxygenase pathway is not involved. Venous thrombosis in the rat was clearly inhibited after oral administration of benzydamine (ED35 8.5 +/- 2.1 mg/kg p.o.). These results indicate that benzydamine possesses antithrombotic properties in the rat which are not based on inhibition of the cyclooxygenase system.
对非甾体抗炎药苄达明(坦通)的抗血栓形成特性进行了研究。在体外,二磷酸腺苷(ADP)和胶原诱导的大鼠血小板聚集受到抑制(半数抑制浓度约为10⁻⁴摩尔/升),而花生四烯酸诱导的犬血小板丙二醛形成未受影响。经典的非甾体抗炎药如吲哚美辛则表现出相反的作用。在体内,苄达明几乎不能抑制花生四烯酸诱导的小鼠肺血栓栓塞,这再次表明其不涉及环氧合酶途径。口服苄达明后,大鼠的静脉血栓形成明显受到抑制(口服半数有效剂量为8.5±2.1毫克/千克)。这些结果表明,苄达明在大鼠中具有抗血栓形成特性,但其并非基于对环氧合酶系统的抑制。